URMC / Research / Clinical Trials / Study Details

UGIE17037 / Dunne mFOLFOX + Chemo IIT / Richard Dunne

Research Question:
Will the use of mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation decrease the rate of distant recurrence among patients with locally advanced esophageal cancer?

Basic Study Information

Purpose:
Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.

Location: University of Rochester Medical Center
Study Reference #: UGIE17037

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Dunne

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Wilmot Research